French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30-Reference-Cited by-同舟云学术

French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30

Published:2020-06-15 Issue:2 Volume:19 Page:191-202
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Nerich Virginie^ORCID,Gamper Eva Maria,Norman Richard,King Madeleine,Holzner Bernhard,Viney Rosalie,Kemmler Georg

Funder

European Organisation for Research and Treatment of Cancer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40258-020-00598-1.pdf

Reference42 articles.

1. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol. 2007;25:191–5. https://doi.org/10.1200/JCO.2006.07.8956.

2. Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102:82–8. https://doi.org/10.1093/jnci/djp472.

3. Frederix GWJ, Severens JL, Hövels AM, Raaijmakers JAM, Schellens JHM. The cloudy crystal ball of cost-effectiveness studies. Value Health. 2013;16:1100–2. https://doi.org/10.1016/j.jval.2013.06.012.

4. Guidelines for the economic evaluation of health technologies: Canada n.d. https://www.cadth.ca/. Accessed17 Sept 2019.

5. National Institute for Health and Care Excellence (NICE). National Institute for Health and Care Excellence (NICE) n.d. https://publications.nice.org.uk/pmg9.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review;PharmacoEconomics;2025-05-21

2. Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets;Scientific Reports;2025-04-28

3. Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France;PharmacoEconomics;2025-04-27

4. Japanese value set for the Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D) cancer-specific preference-based quality of life instrument;2025-04-16

5. Cancer-specific utility instrument for health economic evaluations: A synopsis of the EORTC QLU-C10D user manual and current validity evidence;European Journal of Cancer;2025-02